Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 26, 2024

Efficacy of Trastuzumab and First-Line Taxane Chemotherapy in Patients With MBC With an HER2− Tumor and HER2+ Circulating Tumor Cells

Breast Cancer Research and Treatment


Additional Info

Breast Cancer Research and Treatment
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
Breast Cancer Res Treat 2024 Jan 31;[EPub Ahead of Print], N Verschoor, MK Bos, IE de Kruijff, MN Van, J Kraan, JC Drooger, JM Zuetenhorst, SM Wilting, S Sleijfer, A Jager, JWM Martens

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading